Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $3.5 million.

  • Lipocine's Operating Expenses rose 3212.89% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year decrease of 1955.09%. This contributed to the annual value of $12.4 million for FY2024, which is 1808.31% down from last year.
  • Lipocine's Operating Expenses amounted to $3.5 million in Q3 2025, which was up 3212.89% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, Lipocine's Operating Expenses peaked at $4.4 million during Q1 2024, and registered a low of $1.9 million during Q4 2024.
  • In the last 5 years, Lipocine's Operating Expenses had a median value of $3.1 million in 2022 and averaged $3.2 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 4029.78% in 2023, then crashed by 5030.21% in 2025.
  • Quarter analysis of 5 years shows Lipocine's Operating Expenses stood at $3.3 million in 2021, then fell by 22.44% to $2.6 million in 2022, then rose by 9.71% to $2.8 million in 2023, then plummeted by 30.74% to $1.9 million in 2024, then soared by 78.61% to $3.5 million in 2025.
  • Its Operating Expenses was $3.5 million in Q3 2025, compared to $3.0 million in Q2 2025 and $2.2 million in Q1 2025.